Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.

@article{Maeurer2011HealthCS,
  title={Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.},
  author={Mathias Maeurer and R. Dachsel and Sigrid Domke and Sun{\vc}ica Ries and Gerd Reifschneider and Andreas David Friedrich and Philipp Knorn and Harald Landefeld and Gabriele Niemczyk and Petra Schicklmaier and Colin Wernsd{\"o}rfer and Susanne Windhagen and Holger Albrecht and Stefan Schwab},
  journal={European journal of neurology},
  year={2011},
  volume={18 8},
  pages={1036-45}
}
BACKGROUND AND PURPOSE First-line immunomodulatory treatment with interferon-beta or glatiramer acetate is accepted as effective basic therapy in patients with relapsing-remitting multiple sclerosis (RRMS). However, a considerable portion of patients does not benefit from treatment. METHOD To test basic immunomodulatory treatment under real-life conditions, we retrospectively analyzed clinical and subclinical disease activity within the last 12 months in a cohort of 9916 patients with RRMS… CONTINUE READING